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Abstract 
Background and purpose: We compared the fibrinolytic activity of tenecteplase and 
alteplase in acute ischemic stroke patients, and explored the association between 
hypofibrinogenaemia and intracerebral haemorrhage (ICH). 
Methods: Venous blood samples from a sub-group of participants in the Alteplase-
Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study were obtained at 
pre-treatment, 3-12 hours, and 24±3 hours post intravenous (IV) thrombolysis for analyses of 
plasminogen, Plasminogen Activator Inhibitor-1 (PAI-1), D-Dimer, Factor V, Fibrinogen, 
and Fibrin(ogen) Degradation Products (FDP), in addition to routine coagulation assays. 
Related sample Wilcoxon signed rank tests were used to test the within group changes, and 
independent Mann-Whitney tests for between group differences. 
Results: 30 patients were included (Alteplase=14, tenecteplase=16), with similar baseline 
demographics. Compared to baseline, alteplase caused significant hypofibrinogenaemia 
(p=0.002), prolonged Prothrombin Time (PT) (p=0.011), hypoplasminogenaemia (p=0.001) 
and lower Factor V (p=0.002) at 3-12 hours after administration with persistent 
hypofibrinogenaemia at 24h (p=0.011), while only minor hypoplasminogenaemia (P=0.029) 
was seen in the tenecteplase group. Tenecteplase consumed less plasminogen (p<0.001) and 
fibrinogen (p=0.002) compared with alteplase. 
Conclusion: In acute ischaemic stroke patients, alteplase 0.9mg/kg caused significant 
disruption of the fibrinolytic system while tenecteplase 0.25mg/kg did not, consistent with the 
trend towards lower ICH incidence with tenecteplase in the ATTEST study.  
Clinical trial registration – URL: http://www.clinicaltrials.gov Unique identifier: 
NCT01472926 
  
Introduction 
Intravenous (IV) thrombolysis with alteplase in acute ischaemic stroke (AIS) improves 
clinical outcome, but is associated with an absolute risk of fatal Intracerebral Haemorrhage 
(ICH) of around 2.7%, approximately 7-fold greater odds compared to placebo (OR [95%CI] 
7.14 [3.98-12.79])1. In two phase 2 trials in AIS 2, 3, tenecteplase was associated with a trend 
towards fewer ICH complications.  
As a sub-study of the Alteplase – Tenecteplase Trial Evaluation for Stroke Thrombolysis 
(ATTEST) study, we compared the effects of the two agents on coagulation and the 
fibrinolytic system, and explored potential associations with ICH. 
Methods 
The study protocol of ATTEST has been detailed elsewhere3. Eligible thrombolysis 
candidates within 4.5h of onset were randomised to receive a standard alteplase regime 
(0.9mg/kg) or 0.25mg/kg tenecteplase. This sub-study was initiated part-way through the 
main trial. All trial participants were approached after it commenced. 
Venous blood samples were collected into citrate (final concentration 0.109 M, Greiner Bio-
One, Austria) at baseline (pre-thrombolysis) (Time Point [TP] 1), 3-12 hours (TP2) and 24±3 
hours (TP3) after the initiation of thrombolysis.  Plasma was harvested by centrifugation 
immediately after sampling and stored at -80 °Celsius until analysis. We measured 
Prothrombin Time (PT),  Activated Partial Thromboplastin Time (APTT), fibrinogen, 
Fibrin(ogen) Degradation Products (FDP), plasminogen, D-Dimer, Factor V (FV), PAI-1 
activity, and prothrombin fragment 1+2 (F1+2) at three time points respectively (assay 
methods are detailed in supplementary material Table I.).  
Statistical analysis 
Baseline values were expressed as mean ± standard deviation (SD), changes at TP 2 and TP3 
as mean ± SD percent change from baseline. We used related sample Wilcoxon signed rank 
test to examine the within-groups differences (TP2 vs TP1, TP3 vs TP1), using a Bonferroni 
correction to yield a significance level of p<0.025.  Between-group effects were explored 
with independent Mann-Whitney test.   
Univariate binary logistic regression model was used to explore any association between the 
change of fibrinogen and ICH.  
 
Results 
Of 104 participants in the main ATTEST trial, 30 participated in this sub-study (alteplase=14, 
tenecteplase=16) (See supplementary material Figure I.). Key baseline characteristics were 
similar between groups (Table 1.). 
Effects on coagulation and fibrinolysis (Figure 1.) (Supplementary material Table II.) 
Alteplase was associated with prolongation of PT (p=0.005), reduced fibrinogen (p=0.011) 
and plasminogen (p<0.001), elevated FDP (p=0.002) 24h post thrombolysis, a transient 
drop of Factor V (p=0.002) and increase of D-Dimer (p=0.003) at TP2. In contrast, 
tenecteplase resulted only in elevation of FDP (p=0.009), D-Dimer (p=0.008) up to 24h and 
transient reduction of plasminogen (p=0.029) at TP2.   
Compared to tenecteplase, alteplase induced greater change of PT (p=0.037), fibrinogen 
(p=0.002), plasminogen (p<0.001) and Factor V (p=0.002) at TP2, with sustained differences 
in PT (p=0.031), fibrinogen (p=0.011) and plasminogen (p=0.001) at 24h.  
Association between ICH and depletion of fibrinogen 
Six  patients had haemorrhage post thrombolysis (four with alteplase and two with 
tenecteplase), four classified as Haemorrhagic Infarction4 (HI)1, one as HI2, and one had a 
small Subarachnoid Haemorrhage (SAH). None was considered symptomatic  using either 
ECASS 24 or SITS-MOST criteria5. 
Fibrinogen level dropped below 1g/L at TP2 in two patients, both of whom received alteplase 
(2/30, 14%). This low level persisted at TP3 in one, whose follow-up CT revealed HI2; the 
other patient’s fibrinogen rose to 1.4g/L at TP3, who had SAH. Binary logistic regression 
found no association between ICH and the change of fibrinogen between TP2 and TP1 
(p=0.37).  
Discussion 
Tenecteplase has 15-fold higher fibrin specificity than alteplase6. High fibrin affinity should 
translate into greater potency for thrombolysis, while preserving the integrity of systemic 
coagulation7. AIS trials suggest that tenecteplase may be associated with lower ICH risk with 
similar or superior recanalization compared to alteplase 2, 3. In this sample, alteplase caused 
significant fibrinogen depletion and consumption of plasminogen, and degradation of Factor 
V, while tenecteplase did not.   
Early degradation of fibrinogen is associated with the occurrence of ICH. Matosevic et al8 
reported that within 6 hours post thrombolysis, a decrease of e  2g/L in fibrinogen level was 
an independent predictor for bleeding of all kinds. Significant hypofibrinogaemia (a decrease 
of 2g/L or 50% from baseline) occurs in about one fifth of those receiving IV alteplase, 
whereas a tenecteplase dose escalation study9 showed no severe hypofibrinogenaemia 
(fibrinogen <1g/dL) in any dose (0.1-0.5mg/kg) tested. Similarly, in our sample, tenecteplase 
treatment did not cause hypofibrinogenaemia using either of these criteria. We could not 
replicate an association between hypofibrinogenaemia and ICH, probably due to the small 
sample.  
Limitations of our study include small sample size, variable time of sampling at TP2, and the 
low incidence of serious ICH (none having Parenchymal Haemorrhage, or symptomatic 
clinical deterioration attributable to haemorrhage). Nonetheless, we found significant changes 
in coagulation and fibrinolysis after IV alteplase consistent with the literature, and minimal 
disruption with tenecteplase, consistent with a potentially better safety profile for 
tenecteplase, with retained fibrinolytic efficacy. 
Conclusion 
In acute ischaemic stroke, tenecteplase caused significantly less disruption to the coagulation 
and fibrinolytic systems compared to alteplase. This finding was consistent with the trend 
towards reduced incidence of ICH observed in the ATTEST trial.  
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Table 1. Key demographic and stroke characteristics of the 30 patients  
 Alteplase 
N=14 
Tenecteplase 
N=16 
P value 
Age year 
(mean±SD) 
70±12 69±15 0.95 
Male (n, %) 10 (71%) 10 (63%) 0.71 
OTT mins 
(mean±SD)  
187±52 181±47 0.75 
Baseline NIHSS 
(median, IQR) 
10 (6-15) 11 (8-17) 0.58 
Cardioembolic 
stroke (n, %) 
8 (57%) 8 (50%) 0.7 
Baseline vessel 
occlusion (n, %) 
9 (64%) 8 (50%) 0.34 
Large vessel 
occlusion (ICA, 
M1) (n, %) 
6 (43%) 6 (38%) 0.7 
Sampling time for 
TP2 hours (median, 
IQR, range) 
5.3(4.8-10.1) 
[3.7-11.6] 
4.4(3.9-11.8) 
[3-12.1] 
0.27 
Sampling time for 
TP3 hours (median, 
IQR, range) 
23.8(23.1-24.6) 
[20.9-25.5] 
23.9(23.5-24.6) 
[21.2-25.5] 
0.62 
Diurnal Sampling 
for TP2∗ (n, %) 
1 (7%) 5 (31%) 0.3 
ICA Internal Carotid Artery; M1 Meddle Cerebral Artery M1 Segment; TP Time point; TP2, 2-
12 hours post thrombolysis; TP3, 24±3 hours post thrombolysis; ∗Sampling time between 7 -9 
am. Frequencies were compared using Chi-squared test and Fisher’s test; Mean or median 
values were compared using independent T test and Mann-Whitney U test respectively.  
 
 
 
 
 
 
 
  
Figure 1. The changes of coagulation and fibrinolytic variables in alteplase and tenecteplase treated stroke patients from baseline to 24 
hours post thrombolysis. PT, Prothrombin Time; APTT, Activated Partial Thromboplastin Time; FDP, Fibrin(ogen) Degradation 
Products; PAI-1, Plasminogen Activator Inhibitor-1; F1+2,Prothrombin Fragment 1+2. *Statistical significant difference within or 
between groups. 
